BMS 3Q Revenues: $3.9 billion (-4%) 3Q Earnings: $721 million (+4%) YTD Revenues: $11.6 billion (-3%) YTD Earnings: $2.0 billion (+8%) Comments: Excluding the divested Diabetes Alliance, global revenues increased 7%. Baraclude sales were down 14% to $325 million. Reyataz sales were down 10% to $338 million. Sustiva Franchise sales were $357 million, down 8% and Abilify sales were down 21% to $449 million. Eliquis sales grew by $175 million. Yervoy sales were up 47% to $350 million. Sprycel ...